GDF15

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 11, 2024
Research, GDF15, PSC, Part, Vomiting, Pregnancy, MSS, Liver, Atlas, Preterm birth, NGM, LAIR1, Nausea, Hospital, ILT3, GFRAL, Food and Drug Administration, NASH, Therapy, Woman, Toxicology, Liver disease, CRC, Cirrhosis, Biomarker, Place of birth, Colorectal cancer, Agreement, Acquisition, Plan, FGF19, AASLD, FDA, Food, Weight loss, Primary sclerosing cholangitis, Pembrolizumab, Dehydration, Bile, Hyperemesis gravidarum, HG, Patient, Pre-eclampsia, Malnutrition, Pharmaceutical industry

--On February 26, 2024, announced that it had entered into the Agreement and Plan of Merger with Atlas Neon Parent, Inc., and Atlas Neon Merger Sub, Inc.--

Key Points: 
  • The combination of NGM707 and pembrolizumab was generally well-tolerated at all four doses (200, 600, 1200, 1800 mg) of NGM707.
  • Additional details can be found in NGM Bio’s recent filings with the United States Securities and Exchange Commission (SEC).
  • NGM Bio anticipates that the Offer and the Merger contemplated under the Merger Agreement will be consummated in the second quarter of 2024.
  • If the Merger is effected, NGM Bio’s common stock will be delisted from The Nasdaq Stock Market LLC and NGM Bio will be privately held.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Thursday, March 7, 2024
Liver, School, Liraglutide, Metformin, SCM, GDF15, HKBU, Artesunate, Multimedia, Research, Blood, Obesity, FDA, Fatty liver disease, Exercise, Nausea, Food, GDNF, Trial of the century, Health, Human, Safety, GFRAL, Associate, Patient, Fasting, Insulin, Nature Communications, Tissue, Appetite, Hong Kong Baptist University, Mouse, Public, Pharmaceutical industry

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Thursday, March 7, 2024
Liver, School, Liraglutide, Metformin, SCM, GDF15, HKBU, Artesunate, Research, Blood, Obesity, FDA, Fatty liver disease, Exercise, Nausea, Food, GDNF, Trial of the century, Health, Human, Safety, GFRAL, Associate, Patient, Fasting, Insulin, Nature Communications, Tissue, Appetite, Hong Kong Baptist University, Mouse, Public, Pharmaceutical industry

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

Harmonia Healthcare Launches with a Mission to Revolutionize Female Health

Retrieved on: 
Wednesday, February 21, 2024
Woman, GDF15, Education, Physician, Quality of life, Hyperemesis gravidarum, TIME, Entrepreneurship, Patient, Medicine, Disease, Child, Research, Obstetrics, Nursing

NEW YORK, Feb. 21, 2024 /PRNewswire/ -- Harmonia Healthcare, a specialty women's health platform focusing on underdiagnosed, undertreated, and otherwise dismissed female-specific diseases, launched today. Harmonia intends to open the company's first care center, with a focus on physician-lead research, diagnostic and treatment programs for hyperemesis gravidarum, in late spring. The company is led by a best-in-class founding team including Co-Founder and President Leslie Gautam and Chief Scientific Officer and 2024 TIME Women of the Year honoree Dr. Marlena Fejzo.

Key Points: 
  • Harmonia intends to open the company's first care center, with a focus on physician-lead research, diagnostic and treatment programs for hyperemesis gravidarum, in late spring.
  • Harmonia (@ harmoniahealthcare ) combines the latest in functional medicine treatments with science-backed resolutions, resulting in superior health outcomes and subsequently enhanced well-being and quality of life for women throughout their healthcare journey.
  • "Harmonia's mission is to educate women on the latest developments in research, clinical trials and treatments and act as a trusted ally and reliable advocate throughout their healthcare journeys."
  • To stay up to date on Harmonia, please follow us on Instagram at @ harmoniahealthcare .

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, November 2, 2023
First grade, Research, HS, AD, PD, Food, Safety, Dana–Farber Cancer Institute, Disease, Abstract, Immunology, Cutaneous T-cell lymphoma, Uveal melanoma, STAT3, International, Physician, GDF15, Webcast, Atopic dermatitis, Therapy, Investment, CTCL, Patient, Administration, Cash, Plasma, Lymphoma, Conference, IRAK4, Development, TPD, ASH, Growth, DL2, Hypotension, DL, Solar cycle 4, Arm, AACR, Thrombocytopenia, Fast Track, PTCL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, Society, SD, Hidradenitis suppurativa, MDM2, Recurrence, Blood, Peripheral T-cell lymphoma, Neutropenia, AML, Merkel-cell carcinoma, Pharmaceutical industry, Vaccine, Fine chemical, Medical device, Angela Merkel, Sanofi, Black Majesty

ET

Key Points: 
  • ET
    WATERTOWN, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today reported financial results for the third quarter ended September 30, 2023, and provided business updates on its pipeline of protein degraders.
  • Collaboration Revenues: Collaboration revenues were $4.7 million for the third quarter of 2023 compared to $9.6 million for the third quarter of 2022.
  • Net Loss: Net loss was $52.9 million for the third quarter of 2023 compared to a net loss of $43.0 million for the third quarter of 2022.
  • Cash and Cash Equivalents: As of September 30, 2023, Kymera had $435 million in cash, cash equivalents, and investments.

NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities

Retrieved on: 
Monday, January 9, 2023
Congress, Merck, Retina, AML, GFRAL, Multiple myeloma, NGM, Geographic atrophy, Safety, ILT3, C3, FGF19, ASH, LAIR1, Conference, GDF15, Week, ESMO, AACR, Therapy, Patient, Drug discovery, Macular degeneration, European Society for Medical Oncology, Cancer, SAN, Society, Pancreatic cancer, NASH, Pembrolizumab, Medical imaging, Fine chemical, Pharmaceutical industry, Vaccine

“In 2022, NGM Bio sharpened its focus on oncology solid-tumor clinical development.

Key Points: 
  • “In 2022, NGM Bio sharpened its focus on oncology solid-tumor clinical development.
  • Dr. Woodhouse continued, “Our strategy in 2023 is to focus our clinical development efforts on our portfolio of four clinical-stage oncology programs while operating our prolific drug discovery engine to generate next-generation biologic therapeutics.
  • For our programs outside this area of focus, in retinal disease and NASH, we will seek development partners with relevant domain expertise.
  • Presented additional findings from post-hoc analyses from the CATALINA trial at The Retina Society Annual Scientific Meeting in Q4 2022.

NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
MSD, Private Securities Litigation Reform Act, GDF15, Biology, FGF19, Bias, GFRAL, Failure, U.S. Securities and Exchange Commission, Disease, SEC, SAN, Congress, GLOBE, Fatty liver disease, Retina, NGM, Health, Geographic atrophy, Prostate cancer, Patient, Cancer, Protein engineering, Research, ILT3, Merck & Co., COVID-19, Pancreatic cancer, Cirrhosis, Therapy, LAIR1, NASH, Conference, Nasdaq, Risk, Merck Sharp & Dohme Federal Credit Union, Pembrolizumab, AACR, Liver, Pharmaceutical industry, Medical imaging, Merck

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the quarterly period ended September 30, 2022. 

Key Points: 
  • MK-3655 is an agonistic antibody product candidate binding to fibroblast growth factor receptor 1c-beta-klotho that Merck licensed from NGM Bio.
  • NGM Bio reported a net loss of $47.3million for the quarter ended September30, 2022, compared to a net loss of $28.9 million for the same period in 2021.
  • R&D expenses were $46.1million for the quarter ended September30, 2022, compared to $38.7million for the same period in 2021.
  • NGM Bio expects its cash, cash equivalents and marketable securities will be sufficient to fund its planned operations into the fourth quarter of 2024.

Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER

Retrieved on: 
Tuesday, September 27, 2022
Securities Exchange Act of 1934, Therapy, IOP, Visual Science, Drug Quality and Security Act, Glaucoma, Certificate, USE, Washington University in St. Louis, NEW, European Certification and Qualification Association, Washington University School of Medicine, Securities Act of 1933, Industry, GDF15, Severe cognitive impairment, Forward-looking statement, Survival, Patient, Eye, Retinal ganglion cell, Physician, Regulation, Cell, Neuroprotection, Research, Vascular disease, Intraocular pressure, SEC, Optic nerve, HIV disease progression rates, RGC Resources, Patent, Medical imaging, Pharmaceutical industry, Ophthalmology

NEW YORK , Sept. 27, 2022 /PRNewswire/ -- Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce receipt of a European Certificate of Grant for GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) licensed from the Washington University in St. Louis. Determining the severity of glaucoma using this biomarker will aid in treatment decisions for patients diagnosed with, and being treated for, glaucoma.

Key Points: 
  • Determining the severity of glaucoma using this biomarker will aid in treatment decisions for patients diagnosed with, and being treated for, glaucoma.
  • Q BioMed and its technology partner Mannin Research Inc. are currently developing therapeutics with novel mechanisms of action, to treat Primary Open-Angle Glaucoma.
  • Q BioMed aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers.
  • Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets.

NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic Cancer

Retrieved on: 
Tuesday, September 13, 2022
Lists of diseases, Therapy, American Association for Cancer Research, Particle-size distribution, Health, AACR, Trial of the century, COVID-19, Pancreatic cancer, Prostate, Population, Senior, GFRAL, Private Securities Litigation Reform Act, Retina, Melanoma, American Association, GDF15, Patient, Cancer, U.S. Securities and Exchange Commission, Prognosis, Protein engineering, NGM, Biology, Serum, Nasdaq, Progression-free survival, Liver, MCRPC, Failure, Conference, Large-cell lung carcinoma, Association, GLOBE, SEC, Annual report, Disease, Pharmaceutical industry

The abstracts first author, Andrew Hendifar, M.D., Cedars-Sinai, Samuel Oschin Cancer Center, commented, The preliminary disease control results observed with NGM120 in combination with gemcitabine/Nab-paclitaxel in the Phase 1b cohort merit attention.

Key Points: 
  • The abstracts first author, Andrew Hendifar, M.D., Cedars-Sinai, Samuel Oschin Cancer Center, commented, The preliminary disease control results observed with NGM120 in combination with gemcitabine/Nab-paclitaxel in the Phase 1b cohort merit attention.
  • While a small sample size, seeing two patients in this cohort exhibit partial response beyond 17 months is intriguing.
  • NGM Bio scientists have made several important discoveries related to GDF15, including identification of its cognate receptor, GFRAL.
  • NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease.

NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the ESMO Annual Congress

Retrieved on: 
Tuesday, September 6, 2022
European Society for Medical Oncology, Prostate cancer, COVID-19, Cancer, Retina, PSA, Lists of diseases, Large-cell lung carcinoma, Liver, Disease, Sharp Grossmont Hospital, Financial toxicity, Serum, ESMO, Senior, Prognosis, MCRPC, SEC, Particle-size distribution, NGM, U.S. Securities and Exchange Commission, GLOBE, Protein engineering, Patient, Prostate-specific antigen, Biology, Nasdaq, Therapy, GDF15, Oncology, Failure, Prostate, Congress, GFRAL, Annual report, Melanoma, Private Securities Litigation Reform Act, Health, Trial of the century, Ministry of Education (Malaysia), Pharmaceutical industry, Medical imaging

We are pleased to share these updated findings from the Phase 1a dose escalation trial of NGM120, said Alex DePaoli, M.D., Senior Vice President, Chief Translational Officer at NGM Bio.

Key Points: 
  • We are pleased to share these updated findings from the Phase 1a dose escalation trial of NGM120, said Alex DePaoli, M.D., Senior Vice President, Chief Translational Officer at NGM Bio.
  • While still preliminary, these findings provide an interesting signal that encourages further study of NGM120 for the treatment of patients with advanced prostate cancer.
  • NGM Bio scientists have made several important discoveries related to GDF15, including identification of its cognate receptor, GFRAL.
  • NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease.